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Summary 
 
Peptide YY (PYY) is released following food intake and regulates intestinal function and 
glucose homeostasis, but the mechanisms underpinning these processes are unclear. 
Enteroendocrine L cells contain PYY and express the acylethanolamine receptor, Gpr119. 
Here, we show that Gpr119 activation inhibited epithelial electrolyte secretion in human and 
mouse colon in a glucose-sensitive manner. Endogenous PYY selectively mediated these 
effects, since PYY−/− mice showed no Gpr119 response, but responses were observed in 
NPY−/− mice. Importantly, Gpr119 responses in wild-type (WT) mouse tissue and human 
colon were abolished by Y1 receptor antagonism, but were not enhanced by 
dipeptidylpeptidase IV blockade, indicating that PYY processing to PYY(3-36) was not 
important. In addition, Gpr119 agonism reduced glycemic excursions after oral glucose 
delivery to WT mice but not PYY−/− mice. Taken together, these data demonstrate a 
previously unrecognized role of PYY in mediating intestinal Gpr119 activity and an associated 
function in controlling glucose tolerance. 
Introduction 
 
One of the major roles for intestine-derived peptides is the coordination of digestion with 
nutrient and electrolyte absorption. In addition, several of these peptides, such as glucagon-
like peptide (GLP)-1 and GLP-2, act as incretins, mediating effects on nutrient uptake via 
augmented insulin release from pancreatic β cells (Drucker, 2005). Furthermore, gut 
peptides, including peptide YY (PYY), pancreatic polypeptide (PP), and GLP-1, signal satiety 
to the brain (Gardiner et al., 2008). Enteroendocrine L cells located predominantly in the distal 
ileum and colon of human and rodent intestine (Böttcher et al., 1984 and Arantes and 
Nogueira, 1997) are the primary source of PYY, which is coreleased following food intake 
with proglucagon products, GLP-1 and GLP-2 (Gardiner et al., 2008). 
 Gastrointestinal (GI) function is regulated by enteric nerves, and neuropeptide Y 
(NPY) is an inhibitory neurotransmitter expressed in secretomotor neurons of the submucosal 
plexi (Mongardi Fantaguzzi et al., 2009). Together with PP and the dipeptidylpeptidase IV 
(DPP-IV)-cleaved products NPY(3-36) and PYY(3-36) (Mentlein et al., 1993), NPY and PYY 
exert a range of inhibitory activities, such as slowing gastric emptying, reducing intestinal 
anion and electrolyte secretion (Playford et al., 1990 and Cox and Tough, 2002), and slowing 
intestinal motility, which collectively promote nutrient absorption. Modulation of GI functions 
also has important effects on food intake, energy expenditure, and glucose homeostasis by 
influencing the delivery of nutrients and gut hormones to the circulation. 
 PYY, PYY(3-36), NPY, and NPY(3-36) are prominent intestinal peptides that exert 
their inhibitory actions via different Y receptors. Notably, the antisecretory mucosal 
mechanisms by which these peptides exert their effects are the same in human and mouse 
colon, with Y1 receptor-mediated responses being solely epithelial, while Y2-mediated effects 
are neuronal in origin (Cox and Tough, 2002, Hyland et al., 2003 and Cox, 2007). Anatomical 
and functional studies have shown that Y1 receptors are targeted to basolateral epithelial 
membranes (Mannon et al., 1999 and Cox and Tough, 2002) and would therefore be 
activated by endogenous PYY or NPY released into the subepithelial area. Use of selective 
Y1 and Y2 receptor antagonists together with peptide null mice have allowed us to link 
endogenous PYY and NPY with their cognate receptors. We have shown that Y1-activated 
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intestinal antisecretory effects are predominantly PYY mediated, while NPY preferentially 
stimulates neuronal Y2-mediated mucosal responses (Hyland et al., 2003, Tough et al., 
2006 and Cox, 2008). 
 PYY and proglucagon-derived peptides are copackaged in enteroendocrine L cells 
(Böttcher et al., 1984) that can be activated by a range of lumenal nutrients such as fatty 
acids of different lengths (Anini et al., 1999 and Hirasawa et al., 2005); however, the 
mechanisms that underpin these processes have not been characterized in native tissues. 
Recently, it has been suggested that GI chemosensation is mediated by several unrelated G 
protein-coupled receptors (GPCRs), including Gpr119, Gpr120, and Gpr40 (Engelstoft et al., 
2008). In particular, the expression pattern of Gpr119 is very similar to that of PYY/GLP-1 
containing L cells (Chu et al., 2008), suggesting that Gpr119 stimulation could cause 
significant PYY-related responses as well as GLP-1-mediated effects in the colon and 
elsewhere. The endogenous Gpr119 ligand, oleoylethanolamide (OEA), has been shown to 
reduce food intake and weight gain (Overton et al., 2006) and to increase GLP-1 release from 
L cells in vitro and in vivo (Ahrén et al., 2004 and Reimann et al., 2008). Additionally, Gpr119 
agonism has been shown to improve glucose tolerance in association with enhanced 
glucose-induced circulating insulin concentrations (Overton et al., 2008). Since GLP-1 and 
PYY are copackaged (Böttcher et al., 1984) and coreleased from L cells and both peptides 
have effects on intestinal function and glucose homeostasis (Boey et al., 2007 and Overton 
et al., 2008), it is likely that PYY is also important in mediating Gpr119 responses. 
 The primary aims of this study were therefore to identify the mechanisms by which 
endogenous PYY mediated Gpr119 activity in intact colonic tissue and if so, whether these 
altered epithelial electrolyte secretion and glucose tolerance. To achieve these aims, we 
utilized selective Y receptor antagonists together with specific transgenic mouse models and 
human colon mucosa. A further aim was to establish whether DPP-IV inhibition altered 
Gpr119-activated colonic responses. DPP-IV inhibitors are clinically proven antidiabetics that 
elevate plasma GLP-1 concentrations by prolonging the half-life of this and other peptides. In 
turn, this improves glycemia in type 2 diabetes (Ahrén et al., 2004), in part by prolonging 
insulin release (Demuth et al., 2005) and increasing insulin sensitivity together with a 
beneficial glucagon-lowering capacity (Ahrén, 2009). However, the broad substrate specificity 
of DPP-IV could also reduce the conversion rate of PYY to PYY(3-36) and particularly of NPY 
to NPY(3-36) (Mentlein et al., 1993 and Lambeir et al., 2008), which could have adverse 
effects on other physiological functions. In fact, GI disturbance has been described as a side 
effect of current antidiabetic therapy based on DPP-IV inhibition (sitagliptin), while 
constipation is noted in some patients taking another DPP-IV inhibitor, vildagliptin (Lauster 
et al., 2007). It was therefore of interest to determine whether selective DPP-IV inhibition 
amplified Gpr119-activated colonic responses by prolonging the functional half-life of 
endogenous PYY and/or NPY. 
 
Results 
 
In order to compare responses from the different null mice and human tissue, we first 
established the basal electrophysiological parameters of colonic mucosae from mice of each 
genotype used in this study. The results for wild-type (WT), PYY−/−, NPY−/−, and double 
knockout (NPYPYY−/−) colonic mucosae were similar, while human colonic data were in 
accord with previously published data ( Cox and Tough, 2002 and Tough et al., 2006) (Table 
S1). Epithelial vasoactive intestinal polypeptide (VIP) secretory responses are a consequence 
of Gαs-coupled VPAC receptor stimulation that results in lumenally directed Cl− secretion, and 
this anion movement is measured as an increase in short-circuit current (Isc). Reductions in 
Isc, termed antisecretory responses here, result for example from PYY or NPY stimulating 
epithelial Gαi-coupled Y1 receptors, reducing cAMP-mediated Cl− secretion and attenuating Isc 
levels as a consequence (Cox et al., 1988). Such antisecretory effects were measured to 
three Y receptor agonists (chosen to preferentially stimulate Y1, Y2, or Y4 receptors), and the 
response sizes were the same in WT, single, and double peptide knockout colon (Figure S1). 
Of the genotypes used, only PYY−/− mice showed increased body weight, as seen previously 
with the same knockout (Boey et al., 2006) and a different PYY−/− mouse (Wortley et al., 
2007) (Table S1). Thus, the ablation of PYY, NPY, or both peptides did not alter the 
sensitivity of colonic preparations to VIP or to subsequent Y agonists, and epithelial secretory 
and antisecretory pathways were unaltered. 
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PYY Expression Is Unchanged in NPY−/− Tissue Compared with WT Colon 
 To establish whether deletion of the NPY or PYY gene altered the expression pattern 
of the remaining peptide gene, colonic tissue was analyzed by immunohistochemistry. As 
shown in Figure 1A, PYY-positive L cells were observed throughout the colonic mucosa with 
the same frequency in WT (55.0 ± 4.6 cells/section) and NPY−/− descending colon (56.7 ± 6.8 
cells/section), and as expected, they were absent from PYY−/− or NPYPYY−/− tissues. In the 
descending colon, chromogranin-positive L cells were present with a similar frequency in 
each genotype (data not shown). The frequency and extent of intramural nerve PGP9.5 
labeling was also similar across the genotypes (for example, WT and NPYPYY−/− labeling, 
Figure S2). As expected, NPY-positive innervation was absent from NPYPYY−/− (Figure S2) 
and NPY−/− intestine (data not shown). Taken together with the consistent Y agonist 
sensitivities observed across the genotypes, these predicted patterns of immunolabeling 
confirm the lack of significant compensatory changes in peptide null colon, making them 
appropriate models for functional investigations. 
 
Apical and Basolateral Activation of Gpr119 Reduces Isc in WT Mouse Tissue 
 Direct stimulation of enteroendocrine cells by nutrients provides a general sensing 
mechanism that depends crucially on the presence of different GPCRs (Engelstoft et al., 
2008). Prominent among these is Gpr119, which is stimulated preferentially by lipid amides 
such as endogenous OEA (Overton et al., 2006). As the expression pattern of Gpr119 in the 
GI tract closely resembles that of PYY-expressing L cells, we chose to activate Gpr119 
receptors using the small molecule agonist, PSN632408, which is less lipophilic and more 
selective for Gpr119 than OEA. Overton et al. (2006) showed that PSN632408 (at 10 µM), 
when tested against a panel of 107 GPCRs, channels, and transporters including peroxisome 
proliferator-activated receptor (PPAR)α and transient receptor potential cation channel V1 
(TRPV1), inhibited ≤30% of binding or function. In WT and NPY−/− colon mucosa, PSN632408 
and OEA (10 µM) responses were insensitive to pretreatment with the PPARα antagonist, 
GW6471 (1 µM), and the TRPV1-desensitizing stimulus, capsaicin (2 µM) (Figures S3A–
S3C). 
 In WT colonic mucosa, PSN632408 mimicked the antisecretory effects of PYY, 
basolateral domains (Mannon et al., 1999; Cox and Tough,
2002), we set out to establish whether Gpr119 responses were
also polarized. As clearly shown in Figure 1B, they were not;
PSN632408 addition to apical or basolateral colonic surfaces
reduced the Isc to simil r levels and within a similar time frame.
Importantly, these antisecretory responses were essentially
identical to those of exogenous PYY and NPY in the same tissue
(Cox et al., 2001; Hyland et al., 2003), suggesting a common
pathway. A clear regional variation in Gpr119 sensitivity was
also observed in WT mouse GI tract (Figure 1C), with apical
PSN632408 responses being greatest in the descending olo
and least in duoden l mucosa. This regional Gpr119 sensitivity
correlates with the expression levels of Gpr119 mRNA (Chu
et al., 2008) and L cell distribution, both of which are lowest in
the proximal small intestine and highest in the descending colon
of the mouse (Arantes and Nogueira, 1997) and human GI tract
(Bo¨ttcher et al., 1984). A similar increasing sensitivity to exoge-
nous PYY and NPY has also been described from the small
to the large intestine of the mouse (Cox et al., 2001). It is impor-
tant to note that PSN632408 (10 mM) had no effect on colonic
smooth muscle activity in WT colon, nor were there alterations
in contractile activity to PYY, PYY(3-36), NPY, or PP in the
knockout models compared with WT tissue (data not shown),
and thus we investigated mucosal functions further.
Gpr119 Stimulation with PSN632408 Leads to Y1
Receptor Activation in Mouse Colon
To establish the link between Gpr119 and endogenous PYY or
NPY function in colon mucosa, we test d PSN632408 in the
absence or presence of selective Y receptor antagonists. First,
however, we determined the potency of apical PSN632408.
The consequent sustained reductions in Isc exhibited an EC50
of 5.7 mM (2.2–14.6 mM) (Figure 2A) in WT mouse colon, consis-
tent with a previousmeasure of potency atmouseGpr119 recep-
tors (7.9 ± 0.7 mM) (Overton et al., 2006). The agonist-response
profile was likely to be bell shaped, because 100 mM apical
PSN632408 reduc d Isc by only !7.9 mA/cm2, indicating desen-
sitization. The proposed endogenous Gpr119 ligand, OEA, and
another small molecule agonist, PSN375963 (Overton et al.,
2006), reduced Isc levels to the same degree as PSN632408 in
WT colon (Figure 2A), and this observation was in line with their
published potencies at the murine Gpr119 receptor (Overton
t al., 2006). Using apical PSN632408 (10 mM) as the stimulus
of choice, we then established that the reductions in Isc to
Gpr119 activation were unaltered by pretreatment with the
DPP-IV inhibitor (compound 3) (Lankas et al., 2005), which has
been shown to selectively amplify Y2 receptor- but not Y1-medi-
ated antisecretory effects (Cox, 2008). Colonic PSN632408
responses were, however, inhibited significantly by the Y1
Figure 1. PYY-Positive L Cells in WT and NPY!/! Mouse Colon and Gpr119 Responses in WT Mouse Intestinal Mucosa
(A) Immunohistochemical localization showing distinct PYY-containing L cells in WT and NPY!/!mucosae, but not in PYY!/! or NPYPYY!/!mouse descending
colon. Scale bar, 20 mm throughout.
(B) Example Gpr119 responses to apical (Ap) or basolateral (Bl) PSN632408 (10 mM). The basal Isc levels are shown to the left of each trace, andmucosal area was
0.14 cm2.
(C) Tissue sensitivity to apical PSN632408 (10 mM) in mouse mucosae from duodenum (D), jejunum (J), mid and terminal ileum (MI, TI), and ascending (AC) and
descending colon (DC). Data are the mean ! SEM from 3–14 observations. Background information, including basal electrophysiological parameters, is pre-
sented in Table S1. The pharmacology of selected Y agonist responses in WT versus null mouse colon mucosae are compared in Figure S1, with the patterns
of NPY immunoreactivity in WT and null tissues presented in Figure S2.
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causing long-lasting reductions in Isc (Figure 1B). As Y1 receptors are trafficked selectively to 
epithelial basolateral domains (Mannon et al., 1999 and Cox and Tough, 2002), we set out to 
establish whether Gpr119 responses were also polarized. As clearly shown in Figure 1B, they 
were not; PSN632408 addition to apical or basolateral colonic surfaces reduced the Isc to 
similar levels and within a similar time frame. Importantly, these antisecretory responses were 
essentially identical to those of exogenous PYY and NPY in the same tissue (Cox et al., 
2001 and Hyland et al., 2003), suggesting a common pathway. A clear regional variation in 
Gpr119 sensitivity was also observed in WT mouse GI tract (Figure 1C), with apical 
PSN632408 responses being greatest in the descending colon and least in duodenal 
mucosa. This regional Gpr119 sensitivity correlates with the expression levels of Gpr119 
mRNA (Chu et al., 2008) and L cell distribution, both of which are lowest in the proximal small 
intestine and highest in the descending colon of the mouse (Arantes and Nogueira, 1997) and 
human GI tract (Böttcher et al., 1984). A similar increasing sensitivity to exogenous PYY and 
NPY has also been described from the small to the large intestine of the mouse (Cox et al., 
2001). It is important to note that PSN632408 (10 µM) had no effect on colonic smooth 
muscle activity in WT colon, nor were there alterations in contractile activity to PYY, PYY(3-
36), NPY, or PP in the knockout models compared with WT tissue (data not shown), and thus 
we investigated mucosal functions further. 
 
Gpr119 Stimulation with PSN632408 Leads to Y1 Receptor Activation in Mouse Colon 
 To establish the link between Gpr119 and endogenous PYY or NPY function in colon 
mucosa, we tested PSN632408 in the absence or presence of selective Y receptor 
antagonists. First, however, we determined the potency of apical PSN632408. The 
consequent sustained reductions in Isc exhibited an EC50 of 5.7 µM (2.2–14.6 µM) (Figure 2A) 
in WT mouse colon, consistent with a previous measure of potency at mouse Gpr119 
receptors (7.9 ± 0.7 µM) (Overton et al., 2006). The agonist-response profile was likely to be 
bell shaped, because 100 µM apical PSN632408 reduced Isc by only −7.9 µA/cm2, indicating 
desensitization. The proposed endogenous Gpr119 ligand, OEA, and another small molecule 
agonist, PSN375963 (Overton et al., 2006), reduced Isc levels to the same degree as 
PSN632408 in WT colon (Figure 2A), and this observation was in line with their published 
potencies at the murine Gpr119 receptor (Overton et al., 2006). Using apical PSN632408 (10 
µM) as the stimulus of choice, we then established that the reductions in Isc to Gpr119 
activation were unaltered by pretreatment with the DPP-IV inhibitor (compound 3) (Lankas 
et al., 2005), which has been shown to selectively amplify Y2 receptor- but not Y1-mediated 
antisecretory effects (Cox, 2008). Colonic PSN632408 responses were, however, inhibited 
significantly by the Y1 receptor antagonist (BIBO3304; as were OEA responses) (Figure S3B), 
but they were not affected by Y2 antagonism with BIIE0246 (Figure 2B). Thus, Gpr119 
responses in WT colon are Y1 receptor mediated and are insensitive to DPP-IV blockade. 
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Figure 2. 
Colonic Responses to Gpr119 Agonists Are Y1 Receptor Mediated in Mouse and Human Colon Mucosae 
(A) Concentration response curve for apical PSN632408 (632, n = 3–14), with two concentration data points only for 
apical PSN375963 (375, n = 4–5) and OEA (n = 4–5) in WT mouse colon mucosa. Values are the mean ±SEM 
throughout. 
(B) Apical PSN632408 (10 µM) responses after pretreatment with either compound 3 (+Cpd 3, 1 µM) or the Y1 
antagonist, BIBO3304 (+BIBO, 300 nM), or Y2 antagonism with BIIE0246 (+BIIE, 1 µM) alone or together with 
BIBO3304 (+Both). Data groups (mean − SEM) are compared with control PSN632408 responses (Con). ∗∗p ≤ 0.01. 
(C) Three different agonists (all apical, 10 µM) stimulate Gpr119 responses in WT colon (n = 5 or 14) and NPY−/− (n = 
3–4), but not PYY−/− colon (n = 3–4) or NPYPYY−/− colon (n = 4). Dashed lines show the mean vehicle control values 
(n = 3–4). Agonist responses in peptide knockouts are compared with WT responses. ∗p ≤ 0.05, ∗∗∗p ≤ 0.001. 
(D) Representative Gpr119 responses in human colon mucosa to apical (Ap) or basolateral (Bl) addition of 
PSN632408 (10 µM). Basal Isc values are shown to the left of each trace, and the mucosal area was 0.64 cm2. 
(E) PSN632408 (10 µM) sensitivity to pretreatments with the DPP-IV inhibitor, compound 3 (+Cpd3, 1 µM), GLP-1 
antagonist exendin(9-39) (+9-39, 1 µM), Y1 receptor antagonist BIBO3304 (+BIBO, 300 nM), Y2 antagonist BIIE0246 
alone (+BIIE, 1 µM), Y2 antagonist BIIE0246 together with BIBO3304 (+Both), and BIIE0246 together with BIBO3304 
and exendin(9-39) (+9-39 Both, n = 3–5). Comparisons are made with control PSN632408 responses (Con). ∗p ≤ 
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0.05, ∗∗∗p ≤ 0.001. 
(F) Single concentration (10 µM) effects of apical PSN632408 (632), PSN375963 (375), or OEA (all n = 4) with the 
mean vehicle controls (dashed line) in normal human colon mucosa. Table S1 includes basal electrophysiological 
parameters for mouse and human colon mucosal preparations used in this study. Figures S3A–S3C show that 
PSN632408 and OEA responses are insensitive to blockade of PPARα receptors and TRPV1 desensitization by 
capsaicin in WT and NPY−/− colon. 
 Next, we set out to establish whether neural NPY was necessary for Gpr119 activity. 
To do this, we first investigated whether WT PSN632408 responses were sensitive to 
pretreatment with tetrodotoxin (TTX, 100 nM) and found that they were not (−12.4 ± 2.9 
µA/cm2, n = 4 compared with controls in Figure 2B). We then compared mucosal responses 
to PSN632408, PSN375963, or OEA (at 10 µM) in WT colon with those from NPY−/−, PYY−/−, 
and NPYPYY−/− colon (Figures 2C, S3B, and S3C). Apical responses to the three agonists 
were unchanged (compared to WT responses) in NPY−/− mucosae, but all three were 
significantly inhibited in colon from PYY−/− and NPYPYY−/− mice. The residual apical 
PSN632408 responses in the latter two null tissues were the same as vehicle controls (2.0 ± 
1.4 µA/cm2, dashed lines). Apical OEA responses were also not significantly different in 
NPY−/− compared to WT colon, and they were abolished by Y1 antagonism in tissue from both 
genotypes (Figures S3B and S3C). Basolateral PSN632408 responses were also inhibited 
significantly in PYY−/− (2.0 ± 0.9 µA/cm2, n = 4) and NPYPYY−/− tissue (2.0 ± 0.8 µA/cm2, n = 
4, with vehicle controls of 3.0 ± 3.3 µA/cm2, n = 4) compared with WT basolateral PSN632408 
responses (−11.9 ± 3.5 µA/cm2, n = 4). This demonstrates that ablation of PYY or selective 
blockade of epithelial Y1 receptors (Figure 2B) renders colonic mucosa insensitive to Gpr119 
activation, confirming the functional requirement of Gpr119 mucosal signaling for endogenous 
PYY. 
 Taken together, these findings indicate that apical or basolateral activation of Gpr119 
results in a PYY-mediated, Y1 receptor-specific epithelial response that is observed along the 
length of the intestine and is greatest in the descending colon. Mucosal responses to Gpr119 
agonists do not involve enteric nerves (or NPY) and are not amplified by blockade of DPP-IV 
activity. 
 
Gpr119 Agonist Responses in Human Colon Mucosa 
 Since Gpr119 expression is also significant in human colon (Chu et al., 2008), we set 
out to establish whether mucosal Gpr119 activities were similar in normal human colonic 
mucosa. Apical PSN632408 (10 µM) (Figure 2D) responses closely resembled those of WT 
mouse colon (Figure 1B), although basolateral responses in human colon mucosa were 
slower in onset, probably due to the barrier effect of basolateral connective tissue.  
 Also consistent with our mouse tissue studies, Gpr119 responses in human colon 
were only blocked by the Y1 receptor antagonist, BIBO3304 (Figure 2E). Gpr119 responses in 
human colon were unaffected by pretreatment with the GLP-1 antagonist exendin(9-39) alone 
(Figure 2E), which abolished exendin 4 (100 nM) responses (6.2 ± 2.2 µA/cm2 versus −1.9 ± 
0.5 µA/cm2, n = 4, p < 0.05). These results are consistent with our finding that DPP-IV 
inhibition, which prolongs GLP-1 action, did not affect the mucosal Gpr119 responses in 
mouse colon. Furthermore, neither Y2 antagonism with BIIE0246 nor DPP-IV inhibition had 
any effect on Gpr119 responses in human colon (Figure 2E), again, as observed in WT 
mouse colon. However, in the presence of both Y1 and Y2 antagonists, a small but significant 
increase in Isc was observed following apical PSN632408 addition to human colon. This 
response was abolished by the GLP-1 receptor antagonist exendin(9-39) (Figure 2E), 
indicating that corelease of endogenous GLP-1 with PYY occurs in human colon mucosa 
following Gpr119 stimulation. Only when the Y1 and Y2 receptors were blocked was the small 
GLP-1 secretory (presumably Gαs-coupled) signal revealed in human tissue. As seen in 
mouse mucosae, PSN375963 and OEA (at 10 µM) also reduced Isc to levels similar to those 
observed with PSN632408 in human colon (Figure 2F). Additionally, PSN632408 responses 
were unaffected by nerve block with TTX, resulting in reductions in Isc (−10.4 ± 1.4 µA/cm2, n 
= 3) that were not significantly different from controls (Figure 2F). 
 Taken together, these data suggest that in human colon, PYY mediates the 
predominant antisecretory effects following Gpr119 stimulation and that this mechanism is 
epithelial in origin and exclusively Y1 receptor mediated. Endogenous GLP-1 (and GLP-2) 
meanwhile exert minor exendin(9-39)-sensitive electrogenic responses that are only observed 
when Y1 and Y2 receptors are blocked. 
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Endogenous GLP-1 Does Not Mediate Gpr119 Responses, and Plasma GLP-1 Levels Are 
Unaltered in Null Mice 
 In WT mouse colon mucosa, neither apical nor basolateral PSN632408 responses 
were significantly affected by the GLP-1 receptor antagonist exendin(9-39) (Figure 3A). 
Gpr119 responses were absent from PYY−/− colon, and here too exendin(9-39) had no effect 
on either apical or the residual basolateral responses (Figure 3B). Notably, Gpr119 responses 
were unaltered in NPY−/− colon, and again these mucosal responses were insensitive to 
exendin(9-39) (Figure 3C). Thus, the Gpr119 mucosal responses in the mouse colon are not 
dependent on GLP-1. In addition, we observed small apical PSN632408 responses (−3.0 ± 
1.7 µA/cm2, n = 4) in WT jejunum mucosa that were absent in PYY−/− jejunum (0.0 ± 0.0 
µA/cm2, n = 4). 
 
 To confirm that exendin(9-39) (1 µM) blocked mucosal GLP-1 receptors, we first 
monitored (in WT mouse colon) small increases in Isc to basolateral addition of the GLP-1 
agonist exendin 4 (100 nM, 4.4 ± 1.2 µA/cm2, n = 10). Pretreatment with exendin(9-39) (1 µM) 
inhibited these responses (0.8 ± 0.8 µA/cm2, n = 5, p = 0.07) and significantly reduced 
exendin 4 responses in PYY−/− colon (controls, 6.6 ± 1.3 µA/cm2; after exendin(9-39), 0.7 ± 
0.7 µA/cm2; both n = 3, p ≤ 0.01). Thus, a small secretory GLP-1 response was revealed 
using exendin 4 in WT colon mucosa, and this was unchanged in PYY−/− tissue. 
 Therefore, Gpr119 mucosal sensitivity depends primarily on PYY in both the small 
and large bowel of the mouse, with endogenous GLP-1 playing no significant acute role in the 
colonic Gpr119 response. It should also be noted that the plasma GLP-1 levels of null mice 
were not significantly different from those of their WT counterparts (Figure 3D). 
 
Gpr119 Responses Are Glucose Sensitive in Mouse and Human Colon Mucosae 
 Glucose modulates the activity of isolated L cells (Reimann et al., 2008). In order to 
establish the glucose-sensitivity of L cells in intact tissue, the response to Gpr119 activation 
was analyzed in mucosal preparations from mouse and human colon. When glucose was 
and they were abolished by Y1 antagonism in tissue from both
genotypes (Figures S3B and S3C). Basolateral PSN632408
responses were also inhibited significantly in PYY!/! (2.0 ±
0.9 mA/cm2, n = 4) and NPYPYY!/! tissue (2.0 ± 0.8 mA/cm2,
n = 4, with vehicle controls of 3.0 ± 3.3 mA/cm2, n = 4) com-
pared with WT basolateral PSN632408 responses (!11.9 ±
3.5 mA/cm2, n = 4). This demonstrates that ablation of PYY or
selective blockade of epithelial Y1 receptors (Figure 2B) renders
colonic mucosa insensitive to Gpr119 activation, confirming
the functional requirement of Gpr119 mucosal signaling for
endogenous PYY.
Taken together, these findings indicate that apical or basolat-
eral activation of Gpr119 results in a PYY-mediated, Y1 receptor-
specific epithelial response that is observed along the length of
the intestine and is greatest in the descending colon. Mucosal
responses to Gpr119 agonists do not involve enteric nerves (or
NPY) and are not amplified by blockade of DPP-IV activity.
Gpr119 Agonist Responses in Human Colon Mucosa
Since Gpr119 expression is also significant in human colon (Chu
et al., 2008), we set out to establish whether mucosal Gpr119
activities were similar in normal human colonic mucosa. Apical
PSN632408 (10 mM) (Figure 2D) responses closely resembled
those of WT mouse colon (Figure 1B), although basolateral
responses in human colon mucosa were slower in onset, prob-
ably due to the barrier effect of basolateral connective tissue.
Also consistent with our mouse tissue studies, Gpr119
responses in human colon were only blocked by the Y1 receptor
antagonist, BIBO3304 (Figure 2E). Gpr119 responses in
human colon were unaffected by pretreatment with the GLP-1
antagonist exendin(9-39) alone (Figure 2E), which abolished
exendin 4 (100 nM) responses (6.2 ± 2.2 mA/cm2 versus !1.9 ±
0.5 mA/cm2, n = 4, p < 0.05). These results are consistent with
our finding that DPP-IV inhibition, which prolongs GLP-1 action,
did not affect the mucosal Gpr119 responses in mouse colon.
Furthermore, neither Y2 antagonism with BIIE0246 nor DPP-IV
inhibition had any effect on Gpr119 responses in human colon
(Figure 2E), again, as observed in WT mouse colon. However,
in the presence of both Y1 and Y2 antagonists, a small but signif-
icant increase in Isc was observed following apical PSN632408
addition to human colon. This response was abolished by the
GLP-1 receptor antagonist exendin(9-39) (Figure 2E), indicating
that corelease of endogenous GLP-1 with PYY occurs in
human colon mucosa following Gpr119 stimulation. Only when
the Y1 and Y2 receptors were blocked was th small GLP-1
secretory (presumably Gas-coupled) signal revealed in human
tissue. As seen in mouse mucosae, PSN375963 and OEA (at
10 mM) also reduced Isc to levels similar to those observed
with PSN632408 in human colon (Figure 2F). Additionally,
PSN632408 responses were unaffected by nerve block with
TTX, resulting in reductions in Isc (!10.4 ± 1.4 mA/cm2, n = 3)
that were not significantly different from controls (Figure 2F).
Taken together, these data suggest that in human colon, PYY
mediates the predominant antisecretory effects following
Gpr119 stimulation and that this mechanism is epithelial in origin
and exclusively Y1 receptor mediated. Endogenous GLP-1 (and
GLP-2) meanwhile exert minor exendin(9-39)-sensitive electro-
genic responses that are only observed when Y1 and Y2 recep-
tors are blocked.
Endogenous GLP-1 Does Not Mediate Gpr119
Responses, and Plasma GLP-1 Levels Are Unaltered
in Null Mice
In WT mouse colon mucosa, neither apical nor basolateral
PSN632408 responses were significantly affected by the
GLP-1 receptor antagonist exendin(9-39) (Figure 3A). Gpr119
responses were absent from PYY!/! colon, and here too exen-
din(9-39) had no effect on either apical or the residual basolateral
responses (Figure 3B). Notably, Gpr119 responses were unal-
tered in NPY!/! colon, and again these mucosal responses
were insensitive to exendin(9-39) (Figure 3C). Thus, the Gpr119
mucosal responses in the mouse colon are not dependent on
GLP-1. In addition, we observed small apical PSN632408
responses (!3.0 ± 1.7 mA/cm2, n = 4) in WT jejunum mucosa
that were absent in PYY!/! jejunum (0.0 ± 0.0 mA/cm2, n = 4).
To confirm that exendin(9-39) (1 mM) blocked mucosal GLP-1
receptors, we first monitored (in WT mouse colon) small
increases in Isc to basolateral addition of the GLP-1 agonist
exendin 4 (100 nM, 4.4 ± 1.2 mA/cm2, n = 10). Pretreatment
with exendin(9-39) (1 mM) inhibited these responses (0.8 ±
0.8 mA/cm2, n = 5, p = 0.07) and significantly reduced exendin
4 responses in PYY!/! colon (controls, 6.6 ± 1.3 mA/cm2; after
exendin(9-39), 0.7 ± 0.7 mA/cm2; both n = 3, p % 0.01). Thus,
a small secretory GLP-1 response was revealed using exendin
4 inWT colonmucosa, and this was unchanged in PYY!/! tissue.
Figure 3. Murine Gpr119 Responses Are Not Sided or Dependent on
GLP-1, and Plasma GLP-1 Levels Are Similar across the Genotypes
(A–C) PSN632408 (10 mM) responses after apical (Ap) or basolateral (Bl) addi-
tion ± pretreatment with exendin(9-39) (1 mM) in WT colon (n = 4) (A), in PYY!/!
colon (n = 5) (B), or inNPY!/! colon mucosae (n = 4) (C). Significant differences
between PYY!/! and WT PSN632408 responses are shown (*p % 0.05,
**p% 0.01, ***p% 0.001), and values are the mean ±SEM throughout.
(D) Plasma levels of GLP-1 in each knockout are not significantly different from
WT levels. Values are the mean + SEM (n = 3).
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replaced with mannitol in either reservoir (coincident with the side of PSN632408 addition), 
the Gpr119 responses were significantly reduced in mouse (Figure 4A) and human colon 
mucosa (Figure 4B). In contrast, PYY responses per se were not glucose sensitive, nor were 
the antisecretory effects of the α2-adrenoceptor agonist, UK14,304 (data not shown). The 
sodium/glucose cotransport inhibitor, phloridzin (added apically throughout), was only 
effective when glucose was present apically in both preparations (Figures 4A and 4B, upper 
graphs). Basolateral mannitol replacement predictably had no effect on the small phloridzin 
reductions in Isc (Figures 4A and 4B, lower plots) because the glucose transporter SGLT1 is 
targeted apically. Thus, apical and basolateral Gpr119 receptors can be activated by 
PSN632408 in a glucose-sensitive manner to cause consequent reductions in Isc from mouse 
and human colonic L cells. 
 
 To test whether KATP channels, known to be involved in glucose sensing in isolated L 
cells (Reimann et al., 2008), were involved in basal or Gpr119-activated responses, the KATP 
channel blocker tolbutamide was used (at 1 mM throughout) in the presence of glucose. First, 
apical tolbutamide per se reduced Isc by −17.1 ± 1.5 µA/cm2 (n = 5) in WT tissue, and the 
blocker was significantly less effective in PYY−/− colon (−5.3 ± 1.3 µA/cm2, n = 3, p ≤ 0.01) 
and in Y1 antagonist-pretreated WT tissue (−8.9 ± 2.4 µA/cm2, n = 4, p ≤ 0.05 compared with 
controls). Basolateral tolbutamide exerted an effect similar to apical addition in WT tissue, but 
the reductions in Isc were more variable (data not shown). PYY was released from WT colonic 
mucosa treated with tolbutamide, but not from vehicle controls, and WT tissue total PYY 
levels were not altered significantly (Figure S3D). In WT colon mucosa exposed to apical 
tolbutamide, subsequent apical PSN632408 responses were reduced (from −10.9 ± 1.7 
µA/cm2, n = 6 to −6.6 ± 1.3 µA/cm2, n = 3), but this did not reach statistical significance. We 
conclude that blockade of KATP channels is more efficacious in WT than in PYY−/− mucosa, 
and we suggest that the larger tolbutamide responses observed in WT tissue could be a 
consequence of enhanced PYY release and Y1 receptor activation. In the presence of 
glucose and endogenous PYY, apical Gpr119 activation was partially inhibited by KATP 
channel blockade. 
 
 
 
Therefore, Gpr119 mucosal sensitivity depends primarily on
PYY in both the small and large bowel of the mouse, with endog-
enous GLP-1 playing no significant acute role in the colonic
Gpr119 response. It should also be noted that the plasma
GLP-1 levels of null mice were not significantly different from
those of their WT counterparts (Figure 3D).
Gpr119 Responses Are Glucose Sensitive in Mouse
and Human Colon Mucosae
Glucosemodulates the activity of isolated L cells (Reimann et al.,
2008). In order to establish the glucose-sensitivity of L cells in
intact tissue, th r sp nse to Gpr119 activ tion was analyzed
in muc sal preparations from mouse and human colon. When
glucose was replaced with mannitol in either reservoir (coinci-
dent with the side of PSN632408 addition), the Gpr119
responses were significantly reduced in mouse (Figure 4A) and
human colon mucosa (Figure 4B). In contrast, PYY responses
per se were not glucose sensitive, nor were the antisecretory
effects of the a2-adrenoceptor agonist, UK14,304 (data not
shown). The sodium/glucose cotransport inhibitor, phloridzin
(added apically throughout), was only effective when glucose
was present apically in both preparations (Figures 4A and 4B,
upper graphs). Basolateral mannitol replacement predictably
had no effect on the small phloridzin reductions in Isc (Figures
4A and 4B, lower plots) because the glucose transporter
SGLT1 is targeted apically. Thus, apical and basolateral Gpr119
receptors can be activated by PSN632408 in a glucose-sensitive
manner to cause consequent reductions in Isc from mouse and
human colonic L cells.
To test whether KATP channels, known to be involved in
glucose sensing in isolated L cells (Reimann et al., 2008), were
involved in basal or Gpr119-activated responses, the KATP
c annel bl cker tolbutamide was used (at 1 mM throughout)
in the presence of glucose. First, apical tolbutamide per se
reduced Isc by !17.1 ± 1.5 mA/cm2 (n = 5) in WT tissue, and
the blocker was significantly less effective in PYY!/! colon
(!5.3 ± 1.3 mA/cm2, n = 3, p % 0.01) and in Y1 antagonist-pre-
treated WT tissue (!8.9 ± 2.4 mA/cm2, n = 4, p% 0.05 compared
with controls). Basolateral tolbutamide exerted an effect similar
to apical addition in WT tissue, but the reductions in Isc were
more variable (data not hown). PYY was released from WT
c lonic mucosa treated with t lbutamide, but not from vehicle
controls, and WT tissue total PYY levels were not altered signif-
icantly (Figure S3D). In WT colon mucosa exposed to apical
tolbutamide, subsequent apical PSN632408 responses were
reduced (from !10.9 ± 1.7 mA/cm2, n = 6 to !6.6 ± 1.3 mA/cm2,
n = 3), but this did not reach statistical significance. We conclude
that blockade of KATP channels is more efficacious in WT than in
PYY!/! mucosa, and we suggest that the larger tolbutamide
responses observed in WT tissue could be a consequence of
enhanced PYY release and Y1 receptor activation. In the pres-
ence of glucose and endogenous PYY, apical Gpr119 activation
was partially inhibited by KATP channel blockade.
PYY Mediates the Gpr119 Agonist-Induced
Improvement in Glucose Tolerance
As Gpr119 agonism with PSN632408 induces effects on intes-
tinal function via PYY, we sought to determine whether PYY
Figure 4. Mouse and Human Colon Apical and Basolateral PSN632408 Responses Are Glucose Sensitive
(A) Glucose sensitivity of apical (Ap, n = 7 throughout) or basolateral (Bl, n = 6 throughout) PSN632408 (10 mM) responses in mouse colon mucosa in the presence
of glucose on both sides (11.1 mM, Control) or following mannitol replacement (11.1 mM, + mann) on either side. PYY (10 nM, added basolaterally only) and
phloridzin (Phlor, 50 mM, apical only) responses are also shown. Statistical comparisons are made between agonist or phloridzin responses obtained from tissue
bathed with glucose on both sides (Control) and single-sided mannitol replacement. *p% 0.05, **p% 0.01.
(B) Apical (Ap, n = 3) and basolateral (Bl, n = 3) responses to PSN632408 (10 mM) in human colon mucosa, either in the presence of glucose (black bars) or after
mannitol (11.1 mM, + mann, gray bars) replacement on either side. Values are the mean ! SEM throughout. *p% 0.05.
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PYY Mediates the Gpr119 Agonist-Induced Improvement in Glucose Tolerance 
 As Gpr119 agonism with PSN632408 induces effects on intestinal function via PYY, 
we sought to determine whether PYY mediated other physiological functions of Gpr119 
agonism, such as glucose tolerance. The Gpr119 agonist AR231453 has been shown 
previously to suppress glycemic excursions after oral or intraperitoneal (i.p.) glucose 
administration, particularly when glucose was administered orally (Chu et al., 2007). We 
chose the oral route of administration for both PSN632408 and glucose to maximize effects 
via the intestine (Chu et al., 2007). Our data show that Gpr119 agonism with orally 
administered PSN632408 significantly reduced glycemic excursions after oral glucose 
ingestion in WT mice (Figures 5A and 5B) and resulted in a significant decrease in the area 
under the curve during the first 60 min after glucose ingestion (Figure 5C). This effect of 
PSN632408 on glucose tolerance was associated with a significantly greater plasma insulin 
response to oral glucose, indicated by a longer-lasting elevation of serum insulin 
concentrations after glucose ingestion and a significant increase in the area under the 
resultant curve (Figures 5D, 5E, and 5F, respectively). Interestingly, these PSN632408 
effects were abolished in PYY−/− mice (Figures 5G–5L), demonstrating that PYY is required 
for Gpr119-induced improvement in glucose tolerance and stimulation of circulating insulin 
levels. 
 
Discussion 
 
Our study demonstrates that glucose-sensitive Gpr119 activation causes electrolyte 
antisecretory effects that are most likely due to an increase in endogenous PYY release 
subsequently activating epithelial Y1 receptors (Figure 6) together with improved oral glucose 
tolerance. Importantly, the antisecretory effects following Gpr119 activation are absent from 
PYY−/− and NPYPYY−/− but not from NPY−/− mouse GI tissues, consistent with mediation of 
this process by PYY rather than NPY. Our results also demonstrate that L cell-derived PYY 
and GLP-1 differentially mediate Gpr119 mucosal responses in human colon and that in 
mouse colon, the Gpr119-induced, PYY-mediated antisecretory response is partially 
dependent on KATP channel activity. This L cell mechanism is similar to that described 
recently for GLP-1 release from isolated L cells ( Lauffer et al., 2009 and Tolhurst et al., 
2009), with the notable difference being that Gpr119 receptors are present within both apical 
and basolateral membranes of intact tissue where epithelial polarity is maintained. In addition 
to PYY's ability to slow gastric emptying and regulate satiety and glucose homeostasis, it also 
mediates mucosal responses to Gpr119 stimulation in the small intestine, where efficacy is 
predictably reduced, correlating with the lower L cell frequency in this region relative to the 
distal bowel ( Arantes and Nogueira, 1997 and Sundler et al., 1993). Thus, we conclude that 
intramural and lumenal fatty acid amides have the potential to activate L cells from either a 
blood-borne or lumenal direction to cause PYY/GLP-1 corelease (Figure 6), and this can 
occur along the length of the GI tract. While local GLP-1 and PYY activities differ, e.g., the 
former modulating epithelial barrier function rather than modulating epithelial anion secretion, 
the repertoire of GLP-1 and PYY hormonal activities match more closely, e.g., both reduce 
gastric emptying, inhibit intestinal motility, and modulate vagal afferent output ( Drucker, 
2005 and Dockray, 2009). Mucosal Gpr119 responses were not amplified by DPP-IV 
inhibition, indicating that degradation of full-length PYY to PYY(3-36) is not significant 
following Gpr119 activation in human or mouse colon mucosa. We therefore conclude that 
antidiabetic DPP-IV inhibitors such as vildagliptin may cause constipation, as has been 
observed clinically (Lauster et al., 2007), but that this is unlikely to involve increased stability 
of PYY. 
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  Results from our mechanistic investigations corroborate recent studies utilizing purified 
and single-mouse L cells (Reimann et al., 2008) and signaling studies utilizing endocrine L 
cell-containing lines (Chu et al., 2008 and Lauffer et al., 2009). However, our study also 
demonstrates that PYY is required for the effect of oral Gpr119 agonism with PSN632408 to 
improve oral glucose tolerance and stimulate circulating insulin levels. As Gpr119 is 
expressed in L cells that contain GLP-1, it has been hypothesized that Gpr119 agonism may 
improve glucose tolerance via stimulation of GLP-1 release, as recently reviewed (Overton 
et al., 2008). However, PYY is copackaged with GLPs in L cells (Böttcher et al., 1984) and 
Figure 5. Oral PSN632408 Improves Oral Glucose Tolerance in WT but Not PYY!/! Mice
(A–L) Absolute levels of serum glucose (A andG) and percent of serum glucose values at time 0min (B andH) are shownwith the areas under the resultant glucose
curves (0–60 min) (C and I). The dashed line (B) denotes a significant difference between vehicle and treated groups during 0–60 min by repeated measures.
Serum insulin levels (D and J) are also expressed as a percent of values at time 0 (E and K), with the areas under the resultant insulin curves (0–120 min)
(F and L) in 24 hr fastedWT (A–F) andPYY!/! (G–L)mice after voluntary oral consumption of glucose (3 g/kg bodyweight). At 30min prior to glucose consumption,
mice had voluntarily consumed a paste containing PSN632408 (+632) at a dose of 100 mg/kg or a vehicle control paste (+veh). Data are means + SEM from
7–8 mice per group. *p% 0.05 and **p% 0.01 versus vehicle-treated control mice of the same genotype at specific times.
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has been shown to stimulate insulin sensitivity and improve glucose disposal after acute (van 
den Hoek et al., 2004) or chronic (Pittner et al., 2004 and van den Hoek et al., 2007) 
administration to rodents. Our finding that oral PSN632408 improved oral glucose tolerance 
and enhanced glucose-induced increases in circulating insulin levels in WT but not in PYY−/− 
mice is consistent with the possibility that orally administered PSN632408 can improve oral 
glucose tolerance by L cell Gpr119 agonism with subsequent PYY-mediated effects. 	  
	  	  
 Taken together, these data suggest that Gpr119 has significant effects upon intestinal 
mucosal function, as well as other physiological outcomes such as glucose tolerance, and 
PYY is critical for these effects. Establishing the full repertoire of Gpr119-activated intestinal 
mechanisms that enhance not only GLP-1 but also PYY-mediated responses with 
consequent antihyperglycemic effects now provides an optimal platform for a high-affinity 
Gpr119 agonist to treat diabetes and obesity. 
 
Experimental Procedures 
 
Targeted Deletion of PYY and NPY 
 PYY−/− and NPY−/− mice were generated by homologous recombination in embryonic 
stem cells, as described previously ( Boey et al., 2006 and Karl et al., 2008). NPY−/− and 
PYY−/− mice were crossed to generate double heterozygotes and subsequent double 
knockout NPYPYY−/− mice, which was confirmed by Southern blot analysis and 
immunohistochemistry (Doyle et al., 2008). All mice were on the same C57BL/6-129/SvJ 
background and had free access to standard chow and water ad libitum. Where possible, WT 
littermates were used as controls. Importantly, there was no difference between the WT 
(1:200, 2 hr at room temperature), and nuclei were visualized with DAPI (1:1000
in PBS for 2 min). Sections were washed in PBS, mounted in FluorSave, and
viewed with a Provis microscope fitted with appropriate filters and AxioVision
software. The numbers of endocrine cells were counted per section by an
unbiased observer.
Electrophysiology
Colonic mucosa from clinical specimens or from WT or knockout male mice
(>15 weeks old) was voltage clamped at 0 mV in Ussing chambers, as
described previously (Cox and Tough, 2002; Cox et al., 2001). Vectorial ion
transport wasmeasured continuously as Isc (mA/cm
2), and all peptide additions
were basolateral, as receptors are targeted to the basolateral epithelial
domains. Gpr119 agonist (PSN632408, PSN375963, or OEA) additions were
made to either the apical or basolateral reservoirs 15–20 min following VIP
(10 nM). This is approximately the EC50 concentration of VIP in mouse mucosa
(Cox et al., 2001) and an optimal secretory pretreatment for revealing subse-
quent Gai-coupled epithelial responses in mouse mucosae.
Once stable Isc levels were achieved, mucosae were treat d with the DPP-IV
inhibitor (1 mM compound 3) (Lankas et al., 2005), neuronal activity was
abolished with TTX (100 nM), or endogenous GLP-1 responses were inhibited
with exendin(9-39) (1 mM). Treatment periods were 20–30 min prior to addition
of the Y1 receptor antagonist BIBO3304 (BIBO; 300 nM) or the Y2 selective
antagonist BIIE0246 (BIIE; 1 mM). A concentration of 10 mM PSN632408 was
chosen as the Gpr119 stimulus, as it resulted in near maximal responses in
mouse colon mucosa. Control experiments with Y agonists utilized concentra-
tions that preferentially stimulated either Y1 receptors (10 nM Pro
34PYY), Y2
receptors (30 nM PYY(3-36)), or Y4 receptors (30 nM rPP), as optimized in
previous studies (Cox et al., 2001; Tough et al., 2006). Y agonist-induced
reductions in Isc in epithelia are a result of Gai-coupled attenuation of cAMP
levels with consequent long-lasting decreases in Cl! ion secretion (Cox
et al., 1988). For TRPV1 desensitization, two 1 mM additions of capsaicin (to
both sides) were made, followed by VIP (10 nM) and then either apical
PSN632408 or OEA (10 mM) at 10 min intervals.
In glucose sensitivity studies, tissues were bathed with KH buffer containing
glucose (11.1 mM) on one side and mannitol (11.1 mM) in place of glucose on
the other. Tolbutamide (1 mM) was used to block apical KATP channels, and
changes in basal Isc levels and subsequent Gpr119 responses were recorded.
Peptide Levels and PYY Release
PlasmaGLP-1 wasmeasured in duplicate by an established in-house radioim-
munoassay (Kreymann et al., 1987). The antibody cross-reacted 100%with all
amidated forms of GLP-1 but did not cross-react with glycine-extended forms
(GLP-1(1-37) and GLP-1(7-37)) or any other GI peptides.
For PYY release, mucosae were incubated in 2 ml KH buffer at 37"C with
either vehicle (1%DMSO) or tolbutamide (1 mM) for 90min. PYY-like immuno-
reactivity was measured by an established radioimmunoassay (Adrian et al.,
1985) using antiserum Y21 (at a final dilution of 1:50,000) that cross-reacted
with all biologically active forms of PYY, but not NPY, PP, or other peptides.
The assay was performed in 0.7 ml KH containing 0.3% BSA and was incu-
bated for 3 days at 4"C before separation of free and antibody-bound label.
Oral Glucose Tolerance Test
Male WT and PYY!/!mice at 19–24 weeks of age were used. The oral route of
administration of both PSN632408 and glucose was chosen because GI
effects contribute to effects of Gpr119 agonism. Notably, the effectiveness
of the Gpr119 agonist AR231453 to improve glucose tolerance was reduced
by almost 50% when glucose was given i.p. compared to oral delivery, sug-
gesting incretin involvement in this effect (Chu et al., 2007). Because stress
is known to mask physiological responses to gut hormones (Abbott et al.,
2006), we trained mice to voluntarily eat a vehicle paste followed 30 min later
by a vehicle jelly that would contain PSN632408 and glucose, respectively, on
the day of experimentation, thereby avoiding the stress of oral drug and
glucose administration by gavage. Training and vehicle jelly preparation
were as described previously (Zhang et al., 2010).
Mice were fasted for 24 hr and were then given either vehicle paste or paste
containing 13.5 mg/ml PSN632408 (100 mg/kg) in 24% Gelucire 44/14 and
76% aqueous solution. PSN632408 (25 mg) was first suspended at 65"C in
450 ml preheated Gelucire 44/14. Aqueous solution (1.4 ml) containing
22.1%wt/vol Splenda low calorie sweetener and 7.1% vol/vol imitation straw-
berry flavoring essence was then added to the Gelucire 44/14 and mixed to
form a paste. At 30 min after mice had consumed the entire PSN632408 or
vehicle paste, an oral glucose bolus (3 g/kg) was delivered as a glucose jelly.
To this end, glucose (0.52 g/ml) was incorporated into a jelly containing 4.9%
wt/vol gelatin and 7.5% imitation strawberry flavoring essence. Tail vein
blood was collected at 0, 5, 15, 30, 60, and 120 min after the mouse had
finished eating the glucose jelly, and serum was produced for the determina-
tion of glucose and insulin levels using a glucose oxidase assay and ELISA,
respectively.
Glucose tolerance curves for serum glucose and insulin are presented as
absolute values, as well as percent serum glucose or insulin concentrations
prior to glucose ingestion. Additionally, absolute areas under the serum
glucose or insulin concentration curves were calculated (after subtracting
glucose or insulin concentrations prior to glucose ingestion) between 0 and
60 min (for glucose) or 0 and 120 min (for insulin) after glucose ingestion and
are referred to as area under the curve.
Data Analysis
Functional data from GI tissues measuring the maximal changes in Isc are
expressed as the mean ±SEM per unit area (cm2). Single comparisons were
performed using Student’s unpaired t test, whereas multiple comparisons
utilized one-way ANOVAwith Dunnett’s post hoc test. Changes in PYY release
were compared using Student’s paired t test, and in all cases p % 0.05 was
considered significantly different. Data from in vivo analyses are expressed
Figure 6. The Proposed Paracrine Effects of Gpr119 Activation in
Human and Mouse Colon Mucosa
Stimulation of L cell Gpr119 (a Gas-coupled mechanism) results in degranula-
tion and release of PYY and GLPs (GLP-1 and GLP-2). PYY inhibits epithelial
ion secretion via basolateral Y1 receptor (Gai-coupled) inhibition of cAMP-
dependent Cl! secretion, a process initially activated, for example, via VIP
released from intramural submucosal neurons, resulting in VPAC receptor
(Gas-coupled) activation to increase intraepithelial cAMP and Cl
! secretion
(solid arrow). PYY-mediated inhibition of this process (denoted by dotted
arrows in lumen) results following epithelial Y1 receptor activation. GLP-1
has limited Gas-coupled activity in human epithelia. Additionally, PYY and
GLPs enter the bloodstream, exerting their hormonal influences on peripheral
and central targets, i.e., regulating insulin action, inducing satiety, and control-
ling vagal activity.
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littermates derived from heterozygous breeding compared to WT mice bred separately out of 
these lines, in any of the parameters investigated here or in others not shown here. Mice 
were killed by a Schedule 1 method and tissues were excised for in vitro experimentation. 
 
Immunohistochemistry 
 Lengths (2–3 cm) of mouse descending colon were washed in Krebs-Henseleit (KH) 
buffer, immersed in PFA (4%) for a minimum of 24 hr, washed in PBS, and cryoprotected in 
30% sucrose in PBS for 48 hr before embedding in optimal cutting temperature (OCT) 
compound and storage at −80°C. Sections (15 µm) were cut, rehydrated in PBS, and blocked 
in 10% normal goat serum in PBS for 2 hr before incubating overnight in either polyclonal 
anti-PYY antibody (1:1000) to visualize PYY-containing endocrine cells or in chromogranin A 
(1:400) to label all endocrine cells. Longer incubation times (3–4 days) were used to enable 
anti-NPY labeling (1:400) or protein gene product (PGP) 9.5 (1:400) labeling of all enteric 
neurons. Primary antibodies were visualized with goat anti-rabbit F(ab')2 secondary 
antibodies conjugated to either FITC or TRITC (1:200, 2 hr at room temperature), and nuclei 
were visualized with DAPI (1:1000 in PBS for 2 min). Sections were washed in PBS, mounted 
in FluorSave, and viewed with a Provis microscope fitted with appropriate filters and 
AxioVision software. The numbers of endocrine cells were counted per section by an 
unbiased observer. 
 
Electrophysiology 
 Colonic mucosa from clinical specimens or from WT or knockout male mice (>15 
weeks old) was voltage clamped at 0 mV in Ussing chambers, as described previously (Cox 
and Tough, 2002 and Cox et al., 2001). Vectorial ion transport was measured continuously as 
Isc (µA/cm2), and all peptide additions were basolateral, as receptors are targeted to the 
basolateral epithelial domains. Gpr119 agonist (PSN632408, PSN375963, or OEA) additions 
were made to either the apical or basolateral reservoirs 15–20 min following VIP (10 nM). 
This is approximately the EC50 concentration of VIP in mouse mucosa (Cox et al., 2001) and 
an optimal secretory pretreatment for revealing subsequent Gαi-coupled epithelial responses 
in mouse mucosae. 
 Once stable Isc levels were achieved, mucosae were treated with the DPP-IV inhibitor 
(1 µM compound 3) (Lankas et al., 2005), neuronal activity was abolished with TTX (100 nM), 
or endogenous GLP-1 responses were inhibited with exendin(9-39) (1 µM). Treatment 
periods were 20–30 min prior to addition of the Y1 receptor antagonist BIBO3304 (BIBO; 300 
nM) or the Y2 selective antagonist BIIE0246 (BIIE; 1 µM). A concentration of 10 µM 
PSN632408 was chosen as the Gpr119 stimulus, as it resulted in near maximal responses in 
mouse colon mucosa. Control experiments with Y agonists utilized concentrations that 
preferentially stimulated either Y1 receptors (10 nM Pro34PYY), Y2 receptors (30 nM PYY(3-
36)), or Y4 receptors (30 nM rPP), as optimized in previous studies (Cox et al., 
2001 and Tough et al., 2006). Y agonist-induced reductions in Isc in epithelia are a result of 
Gαi-coupled attenuation of cAMP levels with consequent long-lasting decreases in Cl− ion 
secretion (Cox et al., 1988). For TRPV1 desensitization, two 1 µM additions of capsaicin (to 
both sides) were made, followed by VIP (10 nM) and then either apical PSN632408 or OEA 
(10 µM) at 10 min intervals. 
 In glucose sensitivity studies, tissues were bathed with KH buffer containing glucose 
(11.1 mM) on one side and mannitol (11.1 mM) in place of glucose on the other. Tolbutamide 
(1 mM) was used to block apical KATP channels, and changes in basal Isc levels and 
subsequent Gpr119 responses were recorded. 
 
Peptide Levels and PYY Release 
 Plasma GLP-1 was measured in duplicate by an established in-house 
radioimmunoassay (Kreymann et al., 1987). The antibody cross-reacted 100% with all 
amidated forms of GLP-1 but did not cross-react with glycine-extended forms (GLP-1(1-37) 
and GLP-1(7-37)) or any other GI peptides. 
 For PYY release, mucosae were incubated in 2 ml KH buffer at 37°C with either 
vehicle (1% DMSO) or tolbutamide (1 mM) for 90 min. PYY-like immunoreactivity was 
measured by an established radioimmunoassay (Adrian et al., 1985) using antiserum Y21 (at 
a final dilution of 1:50,000) that cross-reacted with all biologically active forms of PYY, but not 
NPY, PP, or other peptides. The assay was performed in 0.7 ml KH containing 0.3% BSA and 
was incubated for 3 days at 4°C before separation of free and antibody-bound label. 
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Oral Glucose Tolerance Test 
 Male WT and PYY−/− mice at 19–24 weeks of age were used. The oral route of 
administration of both PSN632408 and glucose was chosen because GI effects contribute to 
effects of Gpr119 agonism. Notably, the effectiveness of the Gpr119 agonist AR231453 to 
improve glucose tolerance was reduced by almost 50% when glucose was given i.p. 
compared to oral delivery, suggesting incretin involvement in this effect (Chu et al., 2007). 
Because stress is known to mask physiological responses to gut hormones (Abbott et al., 
2006), we trained mice to voluntarily eat a vehicle paste followed 30 min later by a vehicle 
jelly that would contain PSN632408 and glucose, respectively, on the day of experimentation, 
thereby avoiding the stress of oral drug and glucose administration by gavage. Training and 
vehicle jelly preparation were as described previously (Zhang et al., 2010). 
 Mice were fasted for 24 hr and were then given either vehicle paste or paste 
containing 13.5 mg/ml PSN632408 (100 mg/kg) in 24% Gelucire 44/14 and 76% aqueous 
solution. PSN632408 (25 mg) was first suspended at 65°C in 450 µl preheated Gelucire 
44/14. Aqueous solution (1.4 ml) containing 22.1% wt/vol Splenda low calorie sweetener and 
7.1% vol/vol imitation strawberry flavoring essence was then added to the Gelucire 44/14 and 
mixed to form a paste. At 30 min after mice had consumed the entire PSN632408 or vehicle 
paste, an oral glucose bolus (3 g/kg) was delivered as a glucose jelly. To this end, glucose 
(0.52 g/ml) was incorporated into a jelly containing 4.9% wt/vol gelatin and 7.5% imitation 
strawberry flavoring essence. Tail vein blood was collected at 0, 5, 15, 30, 60, and 120 min 
after the mouse had finished eating the glucose jelly, and serum was produced for the 
determination of glucose and insulin levels using a glucose oxidase assay and ELISA, 
respectively. 
 Glucose tolerance curves for serum glucose and insulin are presented as absolute 
values, as well as percent serum glucose or insulin concentrations prior to glucose ingestion. 
Additionally, absolute areas under the serum glucose or insulin concentration curves were 
calculated (after subtracting glucose or insulin concentrations prior to glucose ingestion) 
between 0 and 60 min (for glucose) or 0 and 120 min (for insulin) after glucose ingestion and 
are referred to as area under the curve. 
 
Data Analysis 
 Functional data from GI tissues measuring the maximal changes in Isc are expressed 
as the mean ±SEM per unit area (cm2). Single comparisons were performed using Student's 
unpaired t test, whereas multiple comparisons utilized one-way ANOVA with Dunnett's post 
hoc test. Changes in PYY release were compared using Student's paired t test, and in all 
cases p ≤ 0.05 was considered significantly different. Data from in vivo analyses are 
expressed as means ±SEM. Differences among groups of mice were assessed by repeated-
measures ANOVA with genotype and treatment as main effects (Statistical Package for the 
Social Sciences, SPSS Inc., version 17.0). Statistical significance was defined as p ≤ 0.05. 
 
Materials 
 BIBO3304 and BIIE0246 were gifts from Boehringer-Ingelheim Pharma KG (Biberach 
an der Riss, Germany), and stock solutions were dissolved in 10% DMSO (at 1 mM) and 
stored at −20°C until required. All peptides were from Bachem Laboratories (St. Helens, UK). 
Stocks were dissolved in water, and aliquots were stored at −20°C, undergoing a single 
freeze-thaw cycle. The DPP-IV inhibitor compound 3 was from R. Roy (Merck, Rahway, NJ) 
(Lankas et al., 2005). PSN632408, PSN375963, and OEA were purchased from Cayman 
Chemical (Ann Arbor, MI) and GW6471 from Tocris Bioscience (Bristol, UK). Anti-PYY (from 
E. Ekblad, University of Lund, Sweden), anti-NPY antibodies (Affiniti Research Products 
Limited, Exeter, UK), goat anti-rabbit FITC- or TRITC-conjugated secondary antibodies 
(Chemicon, Harrow, UK), DAPI (Sigma-Aldrich, Poole, UK), PGP9.5 (Ultraclone Ltd., Isle of 
Wight, UK), and chromogranin A (DAKO A/S, Glostrup, Denmark) were reconstituted and 
stored as recommended by each supplier. OCT and polysine-coated slides were from VWR 
International (Lutterworth, UK) and FluorSave from Calbiochem (Nottingham, UK). Materials 
used for in vivo experimentation were: Splenda Low-Calorie Sweetener (Johnson & Johnson 
Pacific Pty Ltd, Ultimo, Australia), Gelucire 44/14 (Gattefossé, Saint Priest, France, a gift from 
J. Pinder, Trapeze Associates Pty Ltd, Bella Vista, New South Wales, Australia), imitation 
strawberry flavoring essence (Queen Fine Foods Pty Ltd, Alderley, Queensland, Australia), 
glucose (Sigma, St. Louis), gelatin (Gelita Australia Pty Ltd, Botany, New South Wales, 
Australia), glucose oxidase assay kit (Trace Scientific, Noble Park, Victoria, Australia), and 
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insulin ELISA kit (Crystal Chem, Downers Grove, IL). All other compounds were of analytical 
grade from Sigma-Aldrich (Poole, UK). 
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